Bolt Biotherapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Bolt Biotherapeutics (BOLT).

Price Target Range — 8 Quarters

Analyst Consensus — 7 Analysts

3Buy

4Hold

Consensus RatingBuy# Analysts7Avg. Consensus PT$29Upside to Avg. PT+339.7%

Rating Trend — Last 9 Months

Recent Analyst Actions

すべての評価を見る →

Date	Firm	Analyst	Action	Rating Change	Price Target
May 29, 2026	Rodman & Renshaw	Michael G. King Jr.	Initiate	Buy	$22
May 28, 2026	HC Wainwright & Co.	Robert Burns	Maintained	Buy	$7
Mar 13, 2026	HC Wainwright & Co.	Robert Burns	Maintained	Buy	$7
Oct 20, 2025	HC Wainwright & Co.	Robert Burns	Assumes	Buy	$7
Aug 15, 2025	Lake Street	Chad Messer	Maintained	Buy	$4→$75
May 20, 2025	Lake Street	Chad Messer	Initiate	Buy	$80
May 13, 2025	Stifel	Stephen Willey	PT Cut	Hold	$25→$20
Mar 25, 2025	HC Wainwright & Co.	Edward White	Maintained	Neutral	—
Mar 25, 2025	Stifel	Stephen Willey	PT Cut	Hold	$30→$25
Nov 13, 2024	HC Wainwright & Co.	Edward White	Maintained	Neutral	—
Aug 15, 2024	HC Wainwright & Co.	Edward White	Maintained	Neutral	—
May 15, 2024	Leerink Partners	Daina Graybosch	Downgrade	Outperform→Market Perform	$60→$20
May 15, 2024	Jones Trading	Soumit Roy	Downgrade	Buy→Hold	—
May 15, 2024	HC Wainwright & Co.	Edward White	Downgrade	Buy→Neutral	—
May 15, 2024	Stifel	Stephen Willey	Downgrade	Buy→Hold	$120→$30
May 15, 2024	Guggenheim	Michael Schmidt	Downgrade	Buy→Neutral	—
Mar 22, 2024	HC Wainwright & Co.	Edward White	Maintained	Buy	$160

Analyst Ratings News

PRO
Rodman & Renshaw Initiates Coverage On Bolt Biotherapeutics with Buy Rating, Announces Price Target of $22

Rodman & Renshaw analyst Michael G. King Jr. initiates coverage on Bolt Biotherapeutics (NASDAQ:BOLT) with a Buy rating and announces Price Target of $22.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Bolt Biotherapeutics, Maintains $7 Price Target

HC Wainwright & Co. analyst Robert Burns reiterates Bolt Biotherapeutics (NASDAQ:BOLT) with a Buy and maintains $7 price target.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Bolt Biotherapeutics, Maintains $7 Price Target

HC Wainwright & Co. analyst Robert Burns reiterates Bolt Biotherapeutics (NASDAQ:BOLT) with a Buy and maintains $7 price target.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Assumes Bolt Biotherapeutics at Buy, Announces Price Target of $7

HC Wainwright & Co. analyst Robert Burns assumes Bolt Biotherapeutics (NASDAQ:BOLT) with a Buy rating and announces Price Target of $7.

Benzinga Newsdesk

PRO
Lake Street Initiates Coverage On Bolt Biotherapeutics with Buy Rating, Announces Price Target of $4

Lake Street analyst Chad Messer initiates coverage on Bolt Biotherapeutics (NASDAQ:BOLT) with a Buy rating and announces Price Target of $4.

Benzinga Newsdesk

PRO
Stifel Maintains Hold on Bolt Biotherapeutics, Lowers Price Target to $1

Stifel analyst Stephen Willey maintains Bolt Biotherapeutics (NASDAQ:BOLT) with a Hold and lowers the price target from $1.25 to $1.

Benzinga Newsdesk

Bolt Biotherapeutics Inc

ニュース

パートナーシップ

ベンジンガ・グローバル

Bolt Biotherapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Rodman & Renshaw Initiates Coverage On Bolt Biotherapeutics with Buy Rating, Announces Price Target of $22

PRO
HC Wainwright & Co. Reiterates Buy on Bolt Biotherapeutics, Maintains $7 Price Target

PRO
HC Wainwright & Co. Reiterates Buy on Bolt Biotherapeutics, Maintains $7 Price Target

PRO
HC Wainwright & Co. Assumes Bolt Biotherapeutics at Buy, Announces Price Target of $7

PRO
Lake Street Initiates Coverage On Bolt Biotherapeutics with Buy Rating, Announces Price Target of $4

PRO
Stifel Maintains Hold on Bolt Biotherapeutics, Lowers Price Target to $1

People Also Watch

People Also Watch

Bolt Biotherapeutics Inc

ニュース

パートナーシップ

ベンジンガ・グローバル

Bolt Biotherapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRORodman & Renshaw Initiates Coverage On Bolt Biotherapeutics with Buy Rating, Announces Price Target of $22

PROHC Wainwright & Co. Reiterates Buy on Bolt Biotherapeutics, Maintains $7 Price Target

PROHC Wainwright & Co. Reiterates Buy on Bolt Biotherapeutics, Maintains $7 Price Target

PROHC Wainwright & Co. Assumes Bolt Biotherapeutics at Buy, Announces Price Target of $7

PROLake Street Initiates Coverage On Bolt Biotherapeutics with Buy Rating, Announces Price Target of $4

PROStifel Maintains Hold on Bolt Biotherapeutics, Lowers Price Target to $1

People Also Watch

People Also Watch

PRO
Rodman & Renshaw Initiates Coverage On Bolt Biotherapeutics with Buy Rating, Announces Price Target of $22

PRO
HC Wainwright & Co. Reiterates Buy on Bolt Biotherapeutics, Maintains $7 Price Target

PRO
HC Wainwright & Co. Reiterates Buy on Bolt Biotherapeutics, Maintains $7 Price Target

PRO
HC Wainwright & Co. Assumes Bolt Biotherapeutics at Buy, Announces Price Target of $7

PRO
Lake Street Initiates Coverage On Bolt Biotherapeutics with Buy Rating, Announces Price Target of $4

PRO
Stifel Maintains Hold on Bolt Biotherapeutics, Lowers Price Target to $1